The Prevalence and Genotype of Genital (High-Risk) Human Papillomavirus Infections in Female Renal Transplant Recipients
Recruiting
- Conditions
- Cervico-vaginal HPV infectionHuman papillomavirus infection of the cervix10016417
- Registration Number
- NL-OMON35840
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
• Female sex
• Received a renal transplantation at the RUNMC in the period 1968 - 2008
• Age >= 18 years at start of the study
Exclusion Criteria
• Patients not willing to sign and/or return the informed consent form
• Patient is pregnant, or within a period of 3 months after delivery
• Patient is within a period of 3 months after miscarriage
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters are the prevalence of HPV infections and the<br /><br>distribution of different HPV genotypes in our immunocompromised cohort.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints are the prevalence of abnormal PAP smears and of cervical<br /><br>pathology as diagnosed by gynaecological examination and colposcopy.<br /><br><br /><br>Other study parameters:<br /><br>Population characteristics (sociodemographic features, medical data and<br /><br>information regarding sexual behaviour) and experiences of the self-sampling<br /><br>will be evaluated as well. Moreover, we will compare sociodemographic and<br /><br>medical data of the non-responders (i.e. age, marital status and duration of<br /><br>immunosuppression which will retrospectively be collected from the medical<br /><br>charts of these patients) with corresponding data of the responders.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hrHPV persistence in immunosuppressed renal transplant recipients?
How does the prevalence of high-risk HPV genotypes in female RTRs compare to the general population and what implications does this have for vaccine development?
Are there specific biomarkers that correlate with increased risk of hrHPV infection in renal transplant recipients and how can they be used for patient stratification?
What are the most effective management strategies for hrHPV-related cervical dysplasia in immunocompromised transplant patients?
How do current antiviral therapies for HPV infection perform in renal transplant recipients compared to standard-of-care approaches and what combination treatments are being explored?